查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589190

咳嗽过敏症候群治疗药物市场：按药物类别、分销管道划分 - 全球预测 2025-2030 年

Cough Hypersensitivity Syndrome Treatment Market by Drug Class (Anticholinergics, Antihistamines, Antitussive Agents), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

咳嗽过敏症候群治疗药物市场2023年估值为92.1亿美元，预计2024年将达到98.2亿美元，复合年增长率为6.81%，到2030年将达到146.1亿美元，预计将达到1000万美元。

咳嗽过敏症候群（CHS）是一种复杂的临床疾病，其特征是对微不足道的刺激产生过度反应，导致慢性咳嗽。中枢性低通气症候群治疗解决方案的需求源自于对病患生活品质和医疗负担的影响。应用主要集中在针对咳嗽反射途径的先进药物、行为疗法和创新神经调节剂。最终用途广泛，包括医院、专科诊所和研究机构。中枢性低通气症候群 (CHS) 意识的提高、患者人数的增加以及诊断技术的进步推动了市场成长。人工智慧在诊断和个人化医疗中的整合提供了加深市场渗透的机会。因此，投资人工智慧主导的解决方案并与学术研究合作提供了一条创新之路。新兴市场医疗保健支出不断增长等经济趋势进一步支持了潜在的商机。然而，缺乏明确的生物标记和标准化治疗方法使得早期准确诊断变得困难，市场面临限制。此外，监管障碍和高昂的研发成本阻碍了新产品的开发。为了克服这些挑战，公司应该专注于稳健的临床试验并与思想领袖合作。最有希望创新的领域包括非药物干预措施的开发以及包括物理和心理技术在内的多学科治疗方法的探索。此外，继续研究了解中枢性低通气症候群的病理学可能会发现新的治疗标靶。这个市场本​​质上是多学科的，需要药理学研究人员、临床医生和监管专家之间的合作。随着对有效中枢性低通气症候群治疗方案的需求增加，市场相关人员必须利用前沿研究，同时透过策略规划和创新来应对现有挑战。透过使产品满足未满足的临床需求并改善早期诊断工具，公司可以实现显着成长并处于中枢性低通气症候群治疗市场的前沿。

主要市场统计
基准年[2023] 92.1亿美元
预测年份 [2024] 98.2亿美元
预测年份 [2030] 146.1亿美元
复合年增长率（%） 6.81%

市场动态：快速发展的咳嗽过敏症候群治疗市场的主要市场洞察

咳嗽过敏症候群药物市场正在因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 慢性肺部感染疾病高
    • 全球吸烟者人数迅速增加
    • 室内外过敏原的出现
  • 市场限制因素
    • 药物滥用和对咳嗽过敏症候群药物的依赖
  • 市场机会
    • 咳嗽过敏治疗的研发迅速增加
    • 政府针对先进医疗基础设施的倡议
  • 市场挑战
    • 镇咳药物的疗效有限且有不良副作用

波特的五力：驾驭咳嗽过敏症候群药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解咳嗽过敏症候群治疗药物市场的外部影响

外部宏观环境因素在塑造咳嗽过敏症候群治疗药物市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解咳嗽过敏症候群治疗药物市场的竞争状况

对咳嗽过敏症候群治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵咳嗽过敏症候群治疗药物市场供应商的绩效评估

FPNV 定位矩阵是评估咳嗽过敏症候群治疗药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製咳嗽过敏症候群治疗药物市场的成功之路

对咳嗽过敏症候群治疗药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性肺部感染疾病高
      • 世界各地的吸烟者人数正在迅速增加
      • 脆弱的室内和室外过敏原的出现
    • 抑制因素
      • 药物滥用和对咳嗽过敏药物的依赖
    • 机会
      • 治疗咳嗽过敏症候群的研发活动迅速增加
      • 政府致力于先进的医疗基础设施
    • 任务
      • 镇咳药物的功效有限且有不良副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类别分類的咳嗽过敏症候群治疗药物市场

  • 抗胆碱能药物
  • 抗组织胺药
  • 镇咳药
  • 吸入性皮质类固醇
  • 质子帮浦抑制剂
  • 短效β2激动剂

第七章咳嗽过敏症候群治疗药物市场：依通路

  • 医院药房
  • 网路药房
  • 零售药房

第八章北美和南美咳嗽过敏症候群治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太咳嗽过敏症候群治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲咳嗽过敏症候群治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Alvizia Healthcare Private Limited
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche AG
  • Farlex Pharmaceuticals Private Limited
  • GlaxoSmithKline PLC
  • Johnson & Johnson Consumer Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Solace Biotech Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals, Inc.
  • WEEFSEL PHARMA
Product Code: MRR-4311CE1A33E2

The Cough Hypersensitivity Syndrome Treatment Market was valued at USD 9.21 billion in 2023, expected to reach USD 9.82 billion in 2024, and is projected to grow at a CAGR of 6.81%, to USD 14.61 billion by 2030.

Cough Hypersensitivity Syndrome (CHS) represents a complex clinical disorder characterized by an exaggerated response to trivial stimuli, leading to chronic cough. The necessity for CHS treatment solutions arises from its impact on patient quality of life and the healthcare burden it presents. Application primarily focuses on advanced pharmaceuticals, behavioral therapies, and innovative neuromodulators targeting the cough reflex pathway. End-use extends across hospitals, specialty clinics, and research institutes. Market growth is driven by increasing awareness of CHS, expanding patient populations, and advancements in diagnostic methodologies. The integration of artificial intelligence in diagnostics and personalized medicine offers opportunities for deeper market penetration. As such, investing in AI-driven solutions and collaboration with academic research provides a pathway to innovation. Economic trends like increased healthcare spending in emerging markets further boost potential opportunities. However, the market faces limitations due to the lack of definitive biomarkers and standardized treatments, making early and accurate diagnosis challenging. Furthermore, regulatory hurdles and high R&D costs can inhibit new product developments. To navigate these challenges, companies should focus on robust clinical trials and partnerships with key opinion leaders. The most promising areas for innovation include the development of non-pharmacological interventions and exploration of multidisciplinary treatment approaches involving both physical and psychological modalities. Furthermore, continued research into understanding the pathophysiology of CHS could unlock novel therapeutic targets. The market is inherently multidisciplinary, requiring collaboration between pharmacological researchers, clinicians, and regulatory experts. With the increasing demand for effective CHS treatment options, stakeholders in the market must leverage cutting-edge research while addressing existing challenges through strategic planning and innovation. By aligning product offerings with unmet clinical needs and improving early diagnostic tools, businesses can secure significant growth and position themselves at the forefront of the CHS treatment market.

KEY MARKET STATISTICS
Base Year [2023] USD 9.21 billion
Estimated Year [2024] USD 9.82 billion
Forecast Year [2030] USD 14.61 billion
CAGR (%) 6.81%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cough Hypersensitivity Syndrome Treatment Market

The Cough Hypersensitivity Syndrome Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • High prevalence of chronic lung infections diseases
    • Surge in the number of smokers globally
    • Emergence in vulnerable indoor as well as outdoor allergens
  • Market Restraints
    • Drug abuse and dependence on cough hypersensitivity syndrome drugs
  • Market Opportunities
    • Surge in research and development activities in the treatment of cough hypersensitivity syndrome
    • Government initiatives for advanced healthcare infrastructures
  • Market Challenges
    • Limited efficacy and undesirable side effects of antitussives

Porter's Five Forces: A Strategic Tool for Navigating the Cough Hypersensitivity Syndrome Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cough Hypersensitivity Syndrome Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cough Hypersensitivity Syndrome Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cough Hypersensitivity Syndrome Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cough Hypersensitivity Syndrome Treatment Market

A detailed market share analysis in the Cough Hypersensitivity Syndrome Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cough Hypersensitivity Syndrome Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cough Hypersensitivity Syndrome Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cough Hypersensitivity Syndrome Treatment Market

A strategic analysis of the Cough Hypersensitivity Syndrome Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cough Hypersensitivity Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include Alvizia Healthcare Private Limited, AstraZeneca PLC, Bayer AG, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche AG, Farlex Pharmaceuticals Private Limited, GlaxoSmithKline PLC, Johnson & Johnson Consumer Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Solace Biotech Ltd., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals, Inc., and WEEFSEL PHARMA.

Market Segmentation & Coverage

This research report categorizes the Cough Hypersensitivity Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Anticholinergics, Antihistamines, Antitussive Agents, Inhales Corticosteroids, Proton Pump Inhibitors, and Short-Acting Beta-2 Agonists.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High prevalence of chronic lung infections diseases
      • 5.1.1.2. Surge in the number of smokers globally
      • 5.1.1.3. Emergence in vulnerable indoor as well as outdoor allergens
    • 5.1.2. Restraints
      • 5.1.2.1. Drug abuse and dependence on cough hypersensitivity syndrome drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in research and development activities in the treatment of cough hypersensitivity syndrome
      • 5.1.3.2. Government initiatives for advanced healthcare infrastructures
    • 5.1.4. Challenges
      • 5.1.4.1. Limited efficacy and undesirable side effects of antitussives
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cough Hypersensitivity Syndrome Treatment Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anticholinergics
  • 6.3. Antihistamines
  • 6.4. Antitussive Agents
  • 6.5. Inhales Corticosteroids
  • 6.6. Proton Pump Inhibitors
  • 6.7. Short-Acting Beta-2 Agonists

7. Cough Hypersensitivity Syndrome Treatment Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Americas Cough Hypersensitivity Syndrome Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Cough Hypersensitivity Syndrome Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Cough Hypersensitivity Syndrome Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alvizia Healthcare Private Limited
  • 2. AstraZeneca PLC
  • 3. Bayer AG
  • 4. Boehringer Ingelheim GmbH
  • 5. F. Hoffmann-La Roche AG
  • 6. Farlex Pharmaceuticals Private Limited
  • 7. GlaxoSmithKline PLC
  • 8. Johnson & Johnson Consumer Inc.
  • 9. Merck & Co., Inc.
  • 10. Novartis AG
  • 11. Pfizer, Inc.
  • 12. Solace Biotech Ltd.
  • 13. Teva Pharmaceutical Industries Ltd.
  • 14. Vertex Pharmaceuticals, Inc.
  • 15. WEEFSEL PHARMA

LIST OF FIGURES

  • FIGURE 1. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ANTITUSSIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY INHALES CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY PROTON PUMP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY SHORT-ACTING BETA-2 AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 105. COUGH HYPERSENSITIVITY SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023